Current Report Filing (8-k)
October 28 2021 - 6:04AM
Edgar (US Regulatory)
0000910267
false
0000910267
2021-10-27
2021-10-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
October 27, 2021
Titan
Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-13341
|
94-3171940
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
400
Oyster Point Blvd., Suite 505, South
San Francisco, CA 94080
(Address of principal
executive offices and zip code)
650-244-4990
(Registrant's telephone
number including area code)
(Registrant's former
name or former address, if changed since last report)
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
TTNP
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 27, 2021, Titan Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), entered into an amendment (the “Amendment”) to the Employment Agreement
dated April 2, 2019 with Marc Rubin, the Company’s Executive Chairman, to extend the termination date from September 30, 2021 to
December 31, 2022. A copy of the Amendment is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed herewith:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 27, 2021
|
TITAN PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Kate Beebe DeVarney, Ph.D.
|
|
Name:
|
Kate Beebe DeVarney, Ph.D.
|
|
Title:
|
President and Chief Operating Officer
|
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Sep 2023 to Sep 2024